[8-K] Stoke Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (STOK) filed an 8-K noting it issued a press release announcing financial results for the quarter ended September 30, 2025. The filing lists the press release as Exhibit 99.1 and identifies the company’s common stock as trading on the Nasdaq Global Select Market. This is a routine disclosure of quarterly results via press release.

false000162352600016235262025-11-042025-11-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 04, 2025

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38938	47-1144582
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
45 Wiggins Ave
Bedford, Massachusetts				01730
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		STOK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press release issued by Stoke Therapeutics, Inc. regarding its third quarter 2025 financial results, dated November 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			STOKE THERAPEUTICS, INC.
Date:	November 4, 2025	By:	/s/ Thomas E. Leggett
			Thomas E. Leggett Chief Financial Officer

FAQ

What did STOK disclose in this 8-K?

The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025.

Which period do the results cover for STOK?

The results cover the quarter ended September 30, 2025.

What exhibit contains Stoke Therapeutics’ Q3 2025 results?

Exhibit 99.1 contains the press release with the third quarter 2025 financial results.

On which exchange is STOK listed?

Stoke Therapeutics’ common stock trades on the Nasdaq Global Select Market.

What is Stoke Therapeutics’ trading symbol?

The trading symbol is STOK.

When was the press release issued?

The press release was issued on November 4, 2025.